Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04097470
Other study ID # HOVON 155 AML
Secondary ID 2018-000047-3120
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 5, 2019
Est. completion date November 2026

Study information

Verified date January 2023
Source Stichting Hemato-Oncologie voor Volwassenen Nederland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate how safe and effective the addition of the new medicine midostaurin to decitabine is for the treatment of unfit acute myeloid leukemia (AML) and high-risk myelodysplasia (MDS) patients. Patients who are ineligible for intensive chemotherapy because of accompanying diseases may opt for gentler treatment. This does not produce a cure but serves to allow the quality of life to be acceptable for as long as possible. Decitabine is an example of a gentler treatment. It is effective against leukemia and has fewer side effects than intensive chemotherapy. Given in courses of 5 successive days, decitabine is registered for the treatment of AML. There is scientific research to suggest that decitabine is more effective and generally well tolerated when given in courses of 10 successive days. Therefore, treatment with 10-day courses of decitabine is the standard treatment in this scientific research. The aim is to investigate whether this standard treatment can be improved by adding a new product, midostaurin. Midostaurin is a medicine that is directed against a specific protein on leukaemia cells (FLT3).


Description:

This trial aims to develop effective treatments for unfit (i.e. Hematopoietic cell transplantation co-morbidity index (HCT-CI) ≥ 3) in adult (≥ 18 yrs) AML patients, for whom current treatment strategies are highly unsatisfactory. Therefore new treatment modalities are introduced and evaluated in multiple parallel randomized phase II studies that will be conducted within the frame of a master protocol. The scheme of this new design consists of one arm with one of the currently considered best available treatments for unfit AML patients (i.e. 10-day decitabine). After a maximum of 3 10-day courses, or less in case of good response, treatment will be continued with 5-day decitabine courses. This treatment will be compared to investigational treatments in combination with decitabine. The competitor of the 10-day decitabine schedule will be 10-day decitabine combined (sequential) with the tyrosine kinase inhibitor midostaurin (independent of the presence of FLT3 mutations). The rationale for midostaurin is: 1) single agent midostaurin has shown efficacy in both FLT3 wild type and mutant AML; 2) it has shown efficacy in a phase III randomized controlled trial when combined with intensive chemotherapy in FLT3-mutated AML (RATIFY study); 3) midostaurin has been successfully combined with hypomethylating agents (azacitidine and decitabine) and improved the response compared with historical response rates of these drugs, suggesting at least additive affects of midostaurin with hypomethylating agents.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 140
Est. completion date November 2026
Est. primary completion date November 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Patients with: - a diagnosis of AML and related precursor neoplasms according to WHO 2016 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML, or - a diagnosis of myelodysplastic syndrome with excess of blasts (MDS) and International Prognostic Score System (IPSS) > 4.5 - Patients 18 years and older. - Patients NOT eligible for standard chemotherapy, defined as hematopoietic cell transplantation comorbidity index (HCT-CI) = 3. or Patients NOT eligible for standard chemotherapy for other reasons (wish of patient). - White blood cell (WBC) = 30 x109/L (prior hydroxyurea allowed for a maximum of 5 days, stop 2 days before start decitabine treatment) - Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values: - Serum creatinine = 221.7 µmol/L (= 2.5 mg/dL ), unless considered AML-related - Serum bilirubin = 2.5 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert's syndrome - Alanine transaminase (ALT) = 2.5 x ULN, unless considered AML-related - WHO performance status 0, 1 or 2. - Patient is willing and able to use adequate contraception during and until 5 months after the last protocol treatment. - Written informed consent. - Patient is capable of giving informed consent. Exclusion Criteria: - Acute promyelocytic leukemia. - Acute leukemia's of ambiguous lineage according to WHO 2016 - Patient has symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement) - Blast crisis of chronic myeloid leukemia. - Diagnosis of any previous or concomitant malignancy is an exclusion criterion: - except when the patient completed successfully treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 6 months prior to randomization. OR - except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix - Patients previously treated for AML (any antileukemic therapy including investigational agents), a short treatment period ( = 5 days) with Hydroxyurea is allowed - Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea - Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.) - Cardiac dysfunction as defined by: - Myocardial infarction within the last 3 months of study entry, or - Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram or - Unstable angina or - New York Heart Association grade IV congestive heart failure or - Unstable cardiac arrhythmias. - History of stroke or intracranial hemorrhage within 6 months prior to randomization. - Patient has a history of human immunodeficiency virus or active infection with Hepatitis C or B. - Patients known to be pregnant - Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance. - Patients with any serious concomitant medical condition which could, in the opinion of the investigator, compromise participation in the study. - Patients who have senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent. - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Decitabine
Decitabine dosage 20mg/m2 i.v.
Midostaurin
Midostaurin 50 mg b.i.d.

Locations

Country Name City State
Belgium BE-Antwerpen-ZNASTUIVENBERG Antwerpen
Belgium BE-Haine-Saint-Paul-JOLIMONT Haine-Saint-Paul
Belgium BE-Roeselare-AZDELTA Roeselare
Germany DE-Magdeburg-OVGU Magdeburg
Netherlands NL-Amersfoort-MEANDERMC Amersfoort
Netherlands NL-Amsterdam-OLVG Amsterdam
Netherlands NL-Amsterdam-VUMC Amsterdam
Netherlands NL-Arnhem-RIJNSTATE Arnhem
Netherlands NL-Breda-AMPHIA Breda
Netherlands NL-Delft-RDGG Delft
Netherlands NL-Den Bosch-JBZ Den Bosch
Netherlands NL-Den Haag-HAGA Den Haag
Netherlands NL-Doetinchem-SLINGELAND Doetinchem
Netherlands NL-Dordrecht-ASZ Dordrecht
Netherlands NL-Ede-ZGV Ede
Netherlands NL-Eindhoven-CATHARINA Eindhoven
Netherlands NL-Eindhoven-MAXIMAMC Eindhoven
Netherlands NL-Enschede-MST Enschede
Netherlands NL-Groningen-UMCG Groningen
Netherlands NL-Leeuwarden-MCL Leeuwarden
Netherlands NL-Maastricht-MUMC Maastricht
Netherlands NL-Nieuwegein-ANTONIUS Nieuwegein
Netherlands NL-Nijmegen-CWZ Nijmegen
Netherlands NL-Nijmegen-RADBOUDUMC Nijmegen
Netherlands NL-Rotterdam-ERASMUSMC Rotterdam
Netherlands NL-Utrecht-UMCUTRECHT Utrecht
Netherlands NL-Zwolle-ISALA Zwolle
Switzerland CH-Aarau-KSA Aarau
Switzerland CH-Basel-USB Basel
Switzerland CH-Bellinzona-IOSI Bellinzona
Switzerland CH-Bern-INSEL Bern
Switzerland CH-Fribourg-HFR Fribourg
Switzerland CH-Geneve (14)-HCUGE Geneve
Switzerland CH-Lausanne-CHUV Lausanne
Switzerland CH-Luzern-LUKS Luzern
Switzerland CH-St. Gallen-KSSG Saint Gallen
Switzerland CH-Zürich-USZ Zürich

Sponsors (2)

Lead Sponsor Collaborator
Stichting Hemato-Oncologie voor Volwassenen Nederland Swiss Group for Clinical Cancer Research

Countries where clinical trial is conducted

Belgium,  Germany,  Netherlands,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative Complete Remission (CR) / CR with incomplete blood count (CRi) rate Cumulative CR/CRi rate during 3 cycles 4-5 months
Secondary Safety and tolerability of midostaurin determined by the type, frequency, severity and relationship of adverse events to study treatment Safety and tolerability of midostaurin added to 10-day decitabine treatment for AML (type, frequency, severity and relationship of adverse events to study treatment). 5 years
Secondary Efficacy profile The response rate after first three cycles together with the best response during three cycles and after 9 months will determinine the efficacy profile. 4-9 months
Secondary Event free survival (EFS) The time from registration to induction failure, death or relapse whichever occurs first). 5 years
Secondary Overall survival (OS) The time from the date of randomization to the date of death, whatever the cause. Patients still alive at the date last contact will be censored. 5 years
Secondary Hospital stay duration Days of staying in hospital during 3 cycles. 4-5 months
Secondary Transfusion need Number of participants with transfusion needs during 3 cycles. 4-5 months
Secondary Prognostic value of MRD Assessment of the prognostic value of Minimal Residual Disease (MRD) by flowcytometry or PCR 9 months and at relapse
Secondary Predictive value of gene mutations Assessment of the predictive value of gene mutations by exploratory analysis 5 years
Secondary Prognostic value of baseline physical conditions as measured by the short physical performance battery Assessment of the prognostic value of baseline physical and functional conditions using a comprehensive geriatric assessment tool, short physical performance battery (SPPB), on treatment outcome. Total scores (range 0 to 12) will be used to determine physical performance. 5 years
Secondary Prognostic value of baseline functional conditions as measured by the activities of daily living Assessment of the prognostic value of baseline functional conditions using a comprehensive geriatric assessment tool, activities of daily living (ADL), on treatment outcome. Total points (range 0 to 6) will be used to determine functional condition. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05986240 - Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML Phase 1
Active, not recruiting NCT04139434 - Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML Phase 1
Active, not recruiting NCT04318678 - CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) Phase 1
Recruiting NCT05686538 - Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial Phase 2/Phase 3
Terminated NCT04679194 - Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT Phase 1
Recruiting NCT06325748 - SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS Phase 1

External Links